A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Tanaka, Hisashi ^a   Hayashi, Akihito ^a   Morimoto, Takeshi ^a   Taima, Kageaki ^a   Tanaka, Yoshihito ^a   Shimada, Michiko ^a   Kurose, Akira ^b   Takanashi, Shingo ^a   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

Author keywords

EGFR mutation; EML4 ALK; Erlotinib; Lung cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; DOCETAXEL; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MICROTUBULE ASSOCIATED PROTEIN; PEMETREXED; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE METASTASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; EGFR GENE; EML4 ALK GENE; FUSION GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY;

ADENOCARCINOMA; ADULT; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; ONCOGENE PROTEINS, FUSION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84869886632     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-558     Document Type: Article

References (11)

1. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128. 10.1016/S1470-2045(09)70364-X, 20022809.
2. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388. 10.1056/NEJMoa0909530, 20573926.
3. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566. 10.1038/nature05945, 17625570.
4. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27(26):4247-4253. 10.1200/JCO.2009.22.6993, 2744268, 19667264.
5. Kuo YW, Wu SG, Ho CC, Shih JY. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. J Thorac Oncol 2010, 5(12):2039-2040. 10.1097/JTO.0b013e3181f43274, 21102267.
6. Popat S, de Vieira Araújo A, Min T, Swansbury J, Dainton M, Wotherspoon A, Lim E, Nicholson AG, O'Brien ME. Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib. J Thorac Oncol 2011, 6(11):1962-1963. 10.1097/JTO.0b013e31822eec5e, 22005476.
7. Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, Bozzetti C, Sammarelli G, Thai E, Ardizzoni A. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. Lung Cancer 2011, 71(2):241-243. 10.1016/j.lungcan.2010.11.014, 21168933.
8. Zhang X, Zhang S, Yang X, Yang J, Zhou Q, Yin L, An S, Lin J, Chen S, Xie Z, et al. Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression. Mol Cancer 2010, 9:188. 10.1186/1476-4598-9-188, 2908583, 20624322.
9. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14(13):4275-4283. 10.1158/1078-0432.CCR-08-0168, 3025451, 18594010.
10. Camidge DR, Kono SA, Lu X, Okuyama S, Baron AE, Oton AB, Davies AM, Varella-Garcia M, Franklin W, Doebele RC. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011, 6(4):774-780. 10.1097/JTO.0b013e31820cf053, 21336183.
11. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703. 10.1056/NEJMoa1006448, 3014291, 20979469.